Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.

NCT Number	NCT05145400
Lead Sponsor	UNC Lineberger Comprehensive Cancer Center Collaborators: Genzyme, a Sanofi Company
Conditions	Multiple Myeloma, Cancer
Enrollment	50 participants
Start Date	2022-02-18
Primary Completion	2033-05-28 (estimated)
Study Completion	2033-05-28 (estimated)
Updated on ClinicalTrials.gov	2026-06-02